Optimizing Irinotecan Dose for Colorectal Cancer Treatment
Author Information
Author(s): Van Cutsem E, Dirix L, Van Laethem J-L, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H
Primary Institution: University Hospital Gasthuisberg
Hypothesis
Is a higher dose of irinotecan more effective than the standard dose for patients with metastatic colorectal cancer after 5-FU failure?
Conclusion
Individual dose optimization of irinotecan can improve treatment outcomes for patients with metastatic colorectal cancer.
Supporting Evidence
- Overall response rates were 8% in Group A, 13% in Group B, and 9% in Group C.
- Median duration of response was significantly longer in Groups A and B compared to Group C.
- 34% of patients in Group B received a dose of 500 mg/m².
Takeaway
This study looked at how much irinotecan medicine to give to people with a certain type of cancer. Giving more medicine helped some people feel better.
Methodology
This was a prospective, randomised, multicentre, open-label, phase II study comparing different dosing strategies of irinotecan.
Potential Biases
Potential biases due to the open-label design and patient selection criteria.
Limitations
The study had a small sample size and may not be generalizable to all patients with colorectal cancer.
Participant Demographics
Patients had metastatic colorectal cancer, with a median age of 60 years, and a mix of genders.
Statistical Information
P-Value
0.030
Confidence Interval
95% CI 76.14–119.21
Statistical Significance
p=0.030
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website